Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 16/20 | 0.66 |
| ▸ | SPR | P35270 | 2/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.64 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL572511 | 0.91 | SPR (0.78) | ALKSPRIRAK4MAP3K7 | |
| SCHEMBL10270274 | 0.91 | ALK (0.78) | ALKSPRIRAK4MAP3K7MET | |
| SCHEMBL572240 | 0.91 | ALK (0.78) | ALKSPRIRAK4MAP3K7MET | |
| SCHEMBL571730 | 0.86 | SPR (0.51) | ALKSPRIRAK4MAP3K7MET | |
| SCHEMBL571742 | 0.85 | ALK (0.73) | ALKSPRIRAK4METEGFR | |
| SCHEMBL572988 | 0.84 | ALK (0.64) | ALKSPRMET | |
| SCHEMBL17208390 | 0.82 | ALK (0.67) | ALKSPRIRAK4MAP3K7MET | |
| SCHEMBL17210457 | 0.81 | ALK (0.66) | ALKSPRIRAK4MAP3K7MET | |
| SCHEMBL20985426 | 0.81 | IRAK4 (0.72) | SPRIRAK4MAP3K7EGFR | |
| SCHEMBL20985425 | 0.81 | IRAK4 (0.72) | SPRIRAK4MAP3K7EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | ALK 8/4885SPR 4553/4885IRAK4 534/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | ALK 8/4885SPR 4553/4885IRAK4 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.